Stealth BioTherapeutics Corp is a clinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, a structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. This mechanism of action has shown potential clinical benefit in both rare genetic and common age-related ophthalmic and cardiac diseases entailing mitochondrial dysfunction. The Company's second clinical product candidate include SBT-272, for rare neurological diseases involving mitochondrial dysfunction, with a preliminary focus on amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Its clinical product candidate also includes SBT-550 series for rare neurological indications, including Friedreich’s ataxia (FRDA).